Product
PCLX-001
PHARMACEUTICAL
byGreenfire Bio
United States (US)
ABOUT THE PRODUCT
PCLX-001 is a first-in-class NMT1/NMT2 inhibitor currently in Phase 2 clinical trials for refractory colorectal cancer and acute myeloid leukemia (AML).
Information is owner-confirmed
Last updated 4 months ago
Price range